건조 혈반 채취 카드 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 카드 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Dried Blood Spot Collection Cards Market Growth & Trends:

The global dried blood spot collection cards market size is expected to reach at USD 527.10 million in 2030 and is projected to grow at a CAGR of 4.73% from 2025 to 2030. Dried blood spot (DBS) collection cards are used to diagnose infectious diseases, particularly in resource-constrained areas, or to screen newborns for inherited metabolic problems, with a range of novel and innovative DBS uses only lately emerging.

Growing research studies for DBS testing and its advantages for diagnostic purposes are expected to fuel the market growth during the forecast period. In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.

Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology. Dried blood spot collection cards are anticipated to be used as a sample preparation approach in forensic toxicology, and they can cost-effectively retain evidence for closed cases. Screening procedures as well as follow-up of markers of clinical or forensic interest are further toxicological applications where these cards may be progressively utilized.

Developing economies in Africa and Asia have the highest prevalence of rabies. The detection and surveillance of such diseases are hampered by the absence of clinical laboratories. Through dried blood spot collection cards, rabies can be diagnosed with limited resources. As per the data published by the Australian Trade and Investment Commission, Australia has become home to a thriving network of more than 470 biotechnology companies. A high number of established biotechnology and pharmaceutical players and extensive R&D initiatives being undertaken by them are expected to create a high need for DBS testing for therapeutic drug monitoring applications.

Various international organizations such as the U.S. Food and Drug Administration and the World Health Organization acknowledge the role of DBS cards in this pandemic. For instance, In June 2021, Symbiotic, Inc. was granted EUA by the FDA for a COVID-19 self-collect antibody test. This test can be conducted using ELISA with DBS for detecting COVID-19 antibodies in individuals aged 18 years and older, with collecting the sample in children aged 5 years and older by an adult.

The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future. For instance, in July 2022, a study was conducted by researchers from the University of Washington and Med Biotech Laboratories to assess the feasibility of at-home dried blood spot collection along with PCR as a technique for malaria research. The study is anticipated to impact the therapeutic drug and vaccine studies for malaria. Researchers concluded that at-home dried blood spot collection cards for PCR are acceptable, robust, and feasible techniques.

On the other hand, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. Prolonged air drying of the conventional dried blood spot collection cards and contamination between samples during blood collection are some major causes of a high proportion of reactive samples.

Dried Blood Spot Collection Cards Market Report Highlights:

• The New Born Screening (NBS) segment dominated the market with a revenue share of 25.19% in 2024. Advancements in research technologies to improve newborn screening are a major factor driving the market.
• The Whatman 903 segment dominated the market with a share of 40.57% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period.
• Hospitals and clinics dominated the market with a share of 73.33% in 2024. Hospitals and clinics were key end users of DBS collection cards in 2024, owing to mandatory newborn screening in various regions.
• North America dried blood spot collection cards market dominated the global industry with the largest revenue share of 35.03% in 2024. The dominant share can be attributed to the presence of a large number of manufacturers and well-established childcare facilities in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Card Type
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application and card type outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Dried Blood Spot Collection Cards Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Use of DBS Cards in Newborn Screening
    • 3.2.1.2. Increasing Use of DBS Cards in Diagnostic Testing
    • 3.2.1.3. Rise of Forensic Toxicology Applications
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Contamination Caused in DBS Collection Cards
• 3.3. Dried Blood Spot Collection Cards Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Volume Analysis (Instruments)

Chapter 4. Dried Blood Spot Collection Cards Market: Application Estimates & Trend Analysis

• 4.1. Global Dried Blood Spot Collection Cards Market: Application Dashboard
• 4.2. Global Dried Blood Spot Collection Cards Market: Application Movement Analysis
• 4.3. Global Dried Blood Spot Collection Cards Market by Application, Revenue
• 4.4. Newborn Screening
  • 4.4.1. Newborn screening market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Infectious Disease Testing
  • 4.5.1. Infectious disease testing market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Therapeutic Drug Monitoring
  • 4.6.1. Therapeutic drug monitoring market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Forensics
  • 4.7.1. Forensics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. CRO/Research
  • 4.8.1. CRO/Research market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Other Applications
  • 4.9.1. Other applications market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Dried Blood Spot Collection Cards Market: Card Type Estimates & Trend Analysis

• 5.1. Global Dried Blood Spot Collection Cards Market: Card Type Dashboard
• 5.2. Global Dried Blood Spot Collection Cards Market: Card type Movement Analysis
• 5.3. Global Dried Blood Spot Collection Cards Market by Card type, Revenue
• 5.4. Whatman 903
  • 5.4.1. Whatman 903 market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Ahlstrom 225
  • 5.5.1. Ahlstrom 225 market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. FTA
  • 5.6.1. FTA market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Other Card Type
  • 5.7.1. Other card type market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Dried Blood Spot Collection Cards Market: End-use Estimates & Trend Analysis

• 6.1. Global Dried Blood Spot Collection Cards Market: End-use Dashboard
• 6.2. Global Dried Blood Spot Collection Cards Market: End-use Movement Analysis
• 6.3. Global Dried Blood Spot Collection Cards Market by End-use, Revenue
• 6.4. Hospitals & Clinics
  • 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Diagnostic Centers
  • 6.5.1. Diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Dried Blood Spot Collection Cards Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. QIAGEN
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Perkin Elmer
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche Ltd
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Shimazdu Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Ahlstrom-Munksjo
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Pall Corporation
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Eastern Business Forms, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. ARCHIMEDLIFE
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. CENTOGENE AG
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives